News

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President Donald Trump under the International Emergency Economic Powers Act.

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a significant advancement in treatment.

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based procedure.

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term glaucoma management.

Laser surgery is an appropriate adjunctive therapy across the continuum of glaucoma care, as well as a safe option for patients who also have cataracts and other complicating factors

Discover how ellipsoid zone integrity predicts geographic atrophy growth rates in recent clinical trials, enhancing future treatment strategies.

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.

The phase 3 trial observed the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

At ARVO 2025, in Salt Lake City, Utah, Emma Lessieur-Contreras, MD, PhD, talked about her poster on retina extracellular vesicles, and the role that they play on diabetic retinopathy.

Study reveals faricimab effectively treats diabetic macular edema in underrepresented minorities, showing significant visual acuity improvements and safety across diverse patient populations.

Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

At ARVO 2025, in Salt Lake City, Utah, Carly Lam, PhD, MSc, and Tsz Wing Leung, PhD talked about the evaluation of the visual performance of 2 modified DIMS spectacle lens designs.

Investigators were surprised by the outcome of a comparison between the Eyhance and enVista IOLs in low-light conditions.

The Retina World Congress showcases global innovations in surgical and medical retina, highlighting emerging treatments and fostering collaboration among specialists.

Sharon Fekrat, MD, FACS, FASRS, highlights the critical importance of networking and collaboration in the medical field, particularly in ophthalmology.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

The Optegra platform currently operates in the Czech Republic, the Netherlands, Poland, Slovakia and the United Kingdom

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye disease.

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals

Ophthalmologist Dilraj Grewal explores cutting-edge clinical trials for uveitis treatment, highlighting new targeted therapies that aim to control inflammation and macular edema with fewer steroid-related side effects.

Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.

New clinical guidance for anterior and posterior uveitis was published by a research team from the University of Bristol.